ASK1 inhibitors do not appear to affect blood pressure in humans (Selonsertib in adults with pulmonary arterial hypertension and Safety and Efficacy of Selonsertib in Adults With Nonalcoholic Steatohapetitis [NASH] and Bridging [F3] Fibrosis trials16,17,34,35) or in a mouse model of kidney fibrosis associated with hypertension,36 so it is unlikely that the reduction in cardiac fibrosis and cardiomyocyte hypertrophy with selonsertib seen in our studies with Ang II are due to an effect on blood pressure. Here, MAP3K5 is linked to pulmonary arterial hypertension.